Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
5 results loaded, newest first. End of these results.
The company said preclinical data suggest its PRP formulation may make chemotherapy-resistant pancreatic cancer cells more vulnerable to subsequent chemotherapy. A Phase 1b first-in-human study is expected in Q1 2027.
Propanc Biopharma reported results already presented in a newly published peer-reviewed pilot study in Scientific Reports on its PRP proenzyme therapy. Preclinical tests showed PRP slowed tumor growth and reduced spread-related behavior in pancreatic and ovarian cancer models, with tolerable safety. Separate UK Special
Propanc Biopharma said its PRP candidate produced more than 90% mean tumor growth inhibition in pancreatic cancer models. The release also compared the preclinical data with Revolution Medicines' recently approved daraxonrasib.
Propanc Biopharma said it reported preclinical PRP data in advanced pancreatic cancer models and plans a multicenter, open-label Phase 1b first-in-human study in Q1 2027, with PRP holding FDA Orphan Drug Designation for pancreatic cancer.
Propanc Biopharma said its preclinical PRP package showed 90% tumor growth inhibition and more than 2.5-fold survival extension in advanced PDAC models.